856 related articles for article (PubMed ID: 23518370)
1. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
3. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Hla T; Brinkmann V
Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
[TBL] [Abstract][Full Text] [Related]
5. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ
CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Miron VE; Ludwin SK; Darlington PJ; Jarjour AA; Soliven B; Kennedy TE; Antel JP
Am J Pathol; 2010 Jun; 176(6):2682-94. PubMed ID: 20413685
[TBL] [Abstract][Full Text] [Related]
9. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Soliven B; Miron V; Chun J
Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
[TBL] [Abstract][Full Text] [Related]
10. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
11. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Hiestand PC; Rausch M; Meier DP; Foster CA
Prog Drug Res; 2008; 66():361, 363-81. PubMed ID: 18416311
[TBL] [Abstract][Full Text] [Related]
12. S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Gonzalez-Cabrera PJ; Cahalan SM; Nguyen N; Sarkisyan G; Leaf NB; Cameron MD; Kago T; Rosen H
Mol Pharmacol; 2012 Feb; 81(2):166-74. PubMed ID: 22031473
[TBL] [Abstract][Full Text] [Related]
13. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod modulates microglial activation to augment markers of remyelination.
Jackson SJ; Giovannoni G; Baker D
J Neuroinflammation; 2011 Jul; 8():76. PubMed ID: 21729281
[TBL] [Abstract][Full Text] [Related]
15. Central effects of fingolimod.
Cruz VT; Fonseca J
Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
[TBL] [Abstract][Full Text] [Related]
16. Second generation S1P pathway modulators: research strategies and clinical developments.
Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
[TBL] [Abstract][Full Text] [Related]
17. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
18. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod is a potential novel therapy for multiple sclerosis.
Aktas O; Küry P; Kieseier B; Hartung HP
Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
[TBL] [Abstract][Full Text] [Related]
20. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
